Digoxin may short Afib patients' lives, study says; Sun Pharma beats earnings estimates;

@FiercePharma: ICYMI earlier: Dendreon's debt plans could leave stockholders in the lurch. Article | Follow @FiercePharma

@EricPFierce: Merck KGaA has to rely on AZ as its pharma sales contract in Q2. Story | Follow @EricPFierce

@CarlyHFierce: ICYMI earlier: BMS, Pfizer pull out all the stops to give Eliquis sales a Q2 jolt. More | Follow @CarlyHFierce

> A new study found commonly used heart med digoxin may shorten the lives of patients with atrial fibrillation. Story (sub. req.)

> Sun Pharma's first-quarter results topped analyst estimates, pushing shares upward. Report

> Health Canada has OK'd GlaxoSmithKline's ($GSK) plan to address problems at its Quebec-based flu vaccine plant. More

Medical Device News

@FierceMedDev: Private hospitals in China are a priority for med tech Mindray. Story | Follow @FierceMedDev

@StacyALawrence: You're so fierce: A call for nominations of the top women in med tech. Editor's corner | Follow @StacyALawrence

@VarunSaxena2: In a 1st, CMS proposed to cover Cologuard Dx upon FDA approval, so it should get reimbursement faster. FierceDiagnostics story | Follow @VarunSaxena2

@EmilyWFierce: Lung transplant device wins FDA approval, holds potential for critically ill patients with cystic fibrosis. More from the NYT | Follow @EmilyWFierce

> Exact Sciences bags FDA approval and proposed CMS coverage for colorectal cancer screening test. Story

> FDA approves lung preservation device. Item

> Abbott wins Medicare coverage, new tech add-on payments for MitraClip cardiology device. Report

Biotech News

@FierceBiotech: In-depth piece on government's move to roll back oversight on biosecurity research. Article | Follow @FierceBiotech

@DamianFierce: ICYMI: Digging into the FDA's priority review voucher. Who's willing to pay big for one? Story | Follow @DamianFierce

@EmilyMFierce: Using experimental drugs and vaccines against Ebola is ethical, WHO panel says. Report from Science | Follow @EmilyMFierce

> Ear disease biotech Otonomy bags $100M in a booming IPO. Report

> When will Merck KGaA take the M&A plunge? More

> AstraZeneca clears some key PhIII hurdles with lesinurad gout combos. News

> Celltrion targets J&J's Remicade as biosimilars loom in the U.S. Story

Drug Delivery News

> Arrowhead updates TheStreet on clinical trial results of RNAi candidate for hepatitis B. Story

> Can insect venom be harnessed to fight cancer? Article

> Medicated electrospun fabric offers alternative delivery method for HIV-preventing drugs. More

> pH-sensing capsules that deliver optimal quantity of insulin under development. Story

> Oraya receives NIH grant to study use of its novel eye radiation tech against cancer. Article

Diagnostics News

> Novartis, LabCorp and more back Seventh Sense Biosystems' latest financing. Editor's corner

> Northern Ireland outfit advances a rapid but inexpensive heart attack test. Report

> GE Healthcare vet to take on Biocept's Dx reimbursement strategy. More

> Exact Sciences wins FDA approval and more for next-gen colon cancer Dx. Story

> Oxford Immunotec grabs remnants of Colorado rival for a bargain. Article

Pharma Marketing News

> Bye-bye, Incivek: Sovaldi forces Vertex drug off hep C market. Item

> BMS, Pfizer pull out all the stops to give Eliquis sales a Q2 jolt. Article

> Communiqué to sales reps: With today's docs, it's the medium and the message. More

> There's room for more parents, docs on Merck's Gardasil bandwagon. Story

> MannKind recruits Sanofi to hawk Afrezza in $925M marketing deal. Article

And Finally... Canada's government will donate doses of an experimental Ebola vaccine to the World Health Organization. More

Suggested Articles

In a high-stakes patent lawsuit between the CAR-T companies of Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.

Eli Lilly and Boehringer's Jardiance fell short in a heart failure trial in patients with or without diabetes—a test AZ's rival Farxiga recently aced.